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Arany Soosainathan, MB BChir, Hayley M. Moore, MRCS, MBBS, MA,
Manjit S. Gohel, FRCS, MD, FEBVS, and Alun H. Davies, MA, DM, FRCS, London, United Kingdom
Objective: To assess each of the scoring systems used to diagnose and classify post-thrombotic syndrome, a common
chronic complication of deep vein thrombosis. The design of the study was a systematic review of the literature pertaining
to post-thrombotic syndrome.
Methods: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews andMeta-
Analyses (PRISMA) guidelines by a search of PubMed (1948 to September 2011) using the search terms “post-
thrombotic syndrome,” “postthrombotic syndrome,” “post-phlebitic syndrome,” and “postphlebitic syndrome.” A
manual reference list search was also carried out to identify further studies that would be appropriate for inclusion. The
various scoring systems in use were identiﬁed and assessed against a list of criteria to determine their validity for use. For
outcome measures, each scoring system was assessed for speciﬁc criteria, including interobserver reliability, association
with ambulatory venous pressures, ability to assess severity of post-thrombotic syndrome, ability to assess change in
condition over time, and association with patient-reported symptom severity.
Results: The Villalta, Ginsberg, Brandjes, Widmer, CEAP, and Venous Clinical Severity Score systems all were assessed for
the stated outcome measures. From their use in the literature, only the Villalta score was able to fulﬁll all the criteria
described. The main criticism of the Villalta score in the literature appears to be its use of subjective measures. To that
end, we propose that use of a venous disease-speciﬁc quality-of-life questionnaire in combination with the Villalta score
may help standardize the subjective criteria.
Conclusions: The Villalta score, combined with a venous disease-speciﬁc quality-of-life questionnaire, should be considered
the “gold standard” for the diagnosis and classiﬁcation of post-thrombotic syndrome. (J Vasc Surg 2013;57:254-61.)Deep vein thrombosis (DVT) of the lower limbs is
both a common and a serious disease, with an estimated
incidence of 1 per 1000 people per year.1 It can have a clear
precipitant, such as surgery, malignancy, or inherited coag-
ulation disorders, or occur spontaneously. A number of
complications can follow DVT. The incidence and
outcomes of acute complications such as pulmonary embo-
lism are well reported, but post-thrombotic syndrome
(PTS) is less well understood. This is a chronic condition,
occurring in at least one third of patients who have
a DVT.2 It may be associated with leg pain and heaviness,
edema, hyperpigmentation, lipodermatosclerosis, and
venous ulceration, occurring to varying degrees in different
patients. The pathophysiology underlying PTS is thought
to be sustained venous hypertension, resulting from
obstruction to venous ﬂow, vein valvular incompetence,
or a combination. As there is a considerable degree of over-
lap between the acute symptoms resulting from a DVT and
those of PTS, there is a minimum time period (ranging
from 6 months to 2 years in various studies3-5) beforethe Academic Section of Vascular Surgery, Department of Surgery &
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://dx.doi.org/10.1016/j.jvs.2012.09.011the condition is diagnosed. Patients with PTS have a signif-
icantly decreased quality of life6 and the condition can
result in a substantial psychological and economic burden.7
However, although there is a large body of research con-
cerning the natural history and treatment options of acute
DVT, there is less evidence on the diagnosis and manage-
ment of PTS. One of the reasons often cited for this is the
lack of a clear gold standard deﬁnition of PTS. Instead,
several scoring systems are used to both diagnose the
condition and classify its severity. This review aims to
describe the main scoring systems, illustrate how they
have been used in studies investigating PTS, and outline
whether one scoring system demonstrates advantages
over the others.
METHODS
This review was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines.8 The relevant studies and reviews
were found through systematic searches of PubMed (1948
to September 2011). The search terms used were “post-
thrombotic syndrome,” “postthrombotic syndrome,”
“post-phlebitic syndrome,” and “postphlebitic syndrome.”
A manual reference list search was also carried out to identify
further studies that would be appropriate for inclusion. The
titles of the search results were screened with human and
English language limits to identify the studies to be included.
The abstracts and full text of thesewere then examined by two
of the authors (A.S., H.M.) to identify those relevant to this
review’s scope, namely, those that referred to a PTS scoring
system. Articles concerning the upper limb and children
were excluded. All other articles including prospective and
Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram. Summary of search
strategy and results of literature review.
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(>18 years) patients, and lower limbs were included.
Once the relevant articles were obtained, a list of the
main PTS scoring systems in use was made. Each scoring
system was then assessed for validity of use according to
speciﬁc criteria, including interobserver reliability, associa-
tion with ambulatory venous pressures (AVPs), ability to
assess severity of PTS, ability to assess the change in condi-
tion over time, and association with patient-reported
symptom severity.
RESULTS
The search strategy, carried out as described in Fig 1,
resulted in 37 publications that fulﬁlled the inclusion
criteria.
Villalta. The Villalta score is a disease score speciﬁc for
PTS.9 It can be used to both diagnose and categorize the
severity of the condition. It was developed in a cross-
sectional study of 100 patients who were assessed 6 to 36
months after DVT. Points are given for ﬁve symptoms(pain, cramps, heaviness, paresthesia, pruritus) and six
clinical signs (pretibial edema, skin induration, hyperpig-
mentation, redness, venous ectasia, pain on calf compres-
sion). Points are given for each of these 11 descriptors
according to severity (Table I), ranging from 0 for not
present to 3 for severe. Furthermore, if a venous ulcer was
present, the severity of the condition was classiﬁed as
severe, regardless of the presence or absence of other signs
or symptoms. The patient was diagnosed as having PTS if
the Villalta score was $5 or if a venous ulcer was present. A
score of 5-9 signiﬁes mild disease, 10-14 moderate disease,
and $15 severe disease.
The Villalta score was used in several studies to diag-
nose PTS.2,10-15 Five studies used the Villalta score as orig-
inally described, with scores >5 conﬁrming the diagnosis of
PTS and a score >14 denoting severe PTS,2,10,12-15 and
one study used a modiﬁed Villalta score, giving a ﬁnal score
out of 9, with 4 being diagnostic and 7 the threshold for
severe PTS.11 When a diagnosis of PTS is made using the
Villalta score, only one assessment giving a score >5 is
Table I. Villalta’s PTS score9
Symptoms/clinical signs None Mild Moderate Severe
Symptoms
Pain 0 points 1 point 2 points 3 points
Cramps 0 points 1 point 2 points 3 points
Heaviness 0 points 1 point 2 points 3 points
Paresthesia 0 points 1 point 2 points 3 points
Pruritus 0 points 1 point 2 points 3 points
Clinical signs
Pretibial edema 0 points 1 point 2 points 3 points
Skin induration 0 points 1 point 2 points 3 points
Hyperpigmentation 0 points 1 point 2 points 3 points
Redness 0 points 1 point 2 points 3 points
Venous ectasia 0 points 1 point 2 points 3 points
Pain on calf compression 0 points 1 point 2 points 3 points
Venous ulcer Absent Present
PTS, Post-thrombotic syndrome.
Table II. Uses of the Villalta score in various studies
Author (year)
No. enrolled
(completed
follow-up) Application
Prandoni et al2 (1996) 355 (245) Diagnosis
Van Dongen et al10
(2005)
300 (244) Diagnosis
Tick et al11 (2008) 1916 (1668) Diagnosis
Kahn et al12 (2005) 359 Diagnosis
Roumen-Klappe et al13
(2009)
116 (110) Diagnosis
Kahn et al14 (2005) 145 Diagnosis
Roumen-Klappe et al15
(2009)
69 Diagnosis
Kahn et al6 (2002) 41 Classify severity
Kahn et al17 (2011) 43 (39) Classify severity
Prandoni et al3 (1997) 528 Long-term follow-up
Kahn et al16 (2008) 387 (260) Long-term follow-up
Kahn et al17 (2011) 43 (39) Evaluation of treatment
O’Donnell et al18 (2008) 32 (26) Evaluation of treatment
Prandoni et al19 (2005) 120 Evaluation of treatment
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multiple assessments, with a set time interval in between.
The Villata score has also been used as a continuous
measurement for longer-term follow-up3,16 to grade the
severity of the condition6,17 and to assess the effectiveness
of treatments (Table II).17-19 The score has also been
shown to yield reliable consistent results, whether used
by physicians9 or by other health professionals trained in
using the scale.20 As such, use of the Villalta score can be
justiﬁed, whether in clinic settings to monitor the progress
of patients or in studies assessing the impact of treatment.
In addition, Villalta scores in patients with PTS appear
to correlate with patient-perceived quality of life as well as
with clinical measurements thought to be related to the
pathophysiology underlying PTS, thus suggesting the Vil-
lalta score is a valid scale for clinical use.6,21,22 Two studies
assessed both the generic and the disease-speciﬁc health-
related quality of life after DVT.6,21 They showed that
although quality-of-life scores tended to improve from
baseline after DVT, patients who developed PTS had
signiﬁcantly worse disease-speciﬁc quality-of-life scores.6,21
These lower scores were not present on the generic quality-
of-life scores, thus attributing the difference to the
condition.
The results of the two studies, showing how the Villalta
scores correlate with quality-of-life scores, are summarized
in Fig 2.6,21 In these two studies, the Villalta score was used
to categorize PTS into mild, moderate, and severe
(Table I). The Venous Insufﬁciency Epidemiological and
Economic Study/Quality of Life (VEINES-QOL) and
the Venous Insufﬁciency Epidemiological and Economic
Study/Symptoms (VEINES-Sym) are patient-reported
outcome scores that can be computed from a 25-item
questionnaire. The items cover symptoms (heavy legs,
aching legs, swelling, night cramps, heat or burning sensa-
tion, restless legs, throbbing, itching, tingling sensation, leg
pain), limitations in daily activities, change over the past
year, and psychological impact. The VEINES-QOL
summary score aims to measure the overall impact of
venous disease on a patient’s life. The VEINES-Sym scoreis a subscale that measures the speciﬁc impact of symptoms
on daily life. In both measures, lower scores indicate lower
quality of life. The data from Kahn et al6 have remained
unchanged. The data from Kahn et al21 have had the
results listed for mild PTS and moderate PTS amalgamated
but otherwise unprocessed.
In looking at the differences between existing classiﬁca-
tion systems, Kolbach et al22 examined the association
between AVP (measured via invasive methods) and the
scores obtained from the various scoring systems. In this
study, the Villalta score was one of the systems with a strong
association with a high AVP value. However, there was
a caveat to this conclusion; there was a considerable degree
of overlap in AVPs in the different clinical severities of PTS,
indicating that there is not a simplistic linear relationship
between venous hypertension and PTS.
In the absence of a gold standard with which to deﬁne
the PTS, the wide spectrum of disease severity, and hence
the difﬁculty in assessing validity of the various scoring
systems, these surrogate measures (health-related quality
of life and numerical measurements of pathophysiologic
markers of the disease) suggest that the Villalta score corre-
lates with the clinical and physiologic markers of the
disease.
Ginsberg. The Ginsberg score was designed in a cross-
sectional study looking at PTS developing after hip or knee
arthroplasty.5 It diagnosed patients as having PTS if the
patient reported leg pain and swelling of a chronic nature
(daily, for a period of at least 1 month), typical in character
(aggravated by prolonged standing, improved by leg
elevation), occurring at least 6 months after the initial
DVT. Patients could be diagnosed with PTS only if they
had both leg pain and swelling and if there was objective
evidence of valvular incompetence. The presence of
persistent occlusion was not included. The Ginsberg score
was used in a study evaluating the efﬁcacy of graduated
010
20
30
40
50
60
70
Mean VEINES-QOL (2002) Mean VEINES-Sym (2002) Mean VEINES-QOL (2008) Mean VEINES-Sym (2008)
Quality of Life Scores
M
e
a
n
 
S
c
o
r
e
s
None
Mild/Moderate PTS
Severe PTS
Fig 2. Graph demonstrating quality-of-life scores in patients with different degrees of post-thrombotic syndrome
(PTS).6,21
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It also will be used to diagnose PTS in the SOX trial, which
was designed to investigate the effectiveness of compres-
sion stockings in preventing PTS.24 Kahn et al25 compared
the Ginsberg and Villalta scales with respect to the health-
related quality of life of patients and with venous valvular
reﬂux (as a physiologic indicator of chronic venous
disease). In this study, they found that when the Villalta
score was used, almost ﬁve times as many patients were
diagnosed with PTS at 1 year than when the Ginsberg
score was used. They also found that patients diagnosed
with the condition when the Ginsberg score was used had
higher mean numeric Villalta scores and lower quality-of-
life scores, suggesting that the Ginsberg scale only iden-
tiﬁes those patients with more severe disease. Furthermore,
this score does not rate the severity of the condition and
may not include patients with predominantly occlusive
deep venous disease.
Brandjes. The Brandjes score was developed as part of
a trial looking at the effect of compression stockings on
patients with symptomatic proximal DVT.4 In a manner
similar to the Villalta score, points are given for a number
of subjective and objective criteria (Table III). These
criteria were chosen from combined components of other
scoring systems,26,27 and patients were classiﬁed as having
PTS based on their score over two consecutive visits, 3
months apart. A score of 3 or higher (including one
objective criterion) diagnosed mild-moderate PTS,
whereas a score of 4 or more from a list of more severesubjective and objective criteria deﬁned severe PTS.
Furthermore, a venous ulcer scored 4 points whereas all
other criteria scored 1, so any patient who had a venous
ulcer after DVT would be classiﬁed as having severe PTS.
This leads to a problem that is also seen in the Widmer and
the CEAP classiﬁcations, namely, that once a patient
develops a venous ulcer, whether or not it heals, he or she
will always be classiﬁed as having severe PTS. However,
a study by Kolbach et al22 investigating the relationship
between AVP values and PTS score showed a strong
association between severity as assessed by the Brandjes
score and higher mean AVP values.
Widmer. The Widmer classiﬁcation was initially devel-
oped to grade chronic venous insufﬁciency, but it also has
been utilized in studies of PTS.28 The Widmer score is
based purely on clinical signs (Table IV). It was used to
diagnose PTS in the Cochrane Systematic Review evalu-
ating compression therapy for treating PTS.29 In the study
by Kolbach et al22 investigating the difference between
scoring systems, the Widmer classiﬁcation showed
a moderate association with the Brandjes score and the
CEAP score (k ¼ 0.52 and k ¼ 0.53, respectively).
However, this review also noted that because clinical signs
rarely change over time, except with deterioration, the
Widmer score would not be ideal to use for measuring the
outcome of treatment of PTS.
CEAP. The CEAP score was designed to score all
chronic venous disease, categorizing patients’ disease
according to their clinical signs (C), etiology (E), anatomic
Table III. Brandjes scoring system4
Subjective criteria Objective criteria
Symptoms Score Sign Score
Spontaneous pain in calf 1 Calf circumference increased by 1 cm 1
Spontaneous pain in thigh 1 Ankle circumference increased by 1 cm 1
Pain in calf on standing/walking 1 Pigmentation 1
Pain in thigh on standing/walking 1 Venectasia 1
Edema of foot/calf 1 Newly formed varicosis 1
“Heaviness” of leg 1 Phlebitis 1
Spontaneous pain and pain on walking/standing 1 Venous ulcer 4
Impairment of daily activities 1
Table IV. Widmer scoring system28
Stage Symptoms
1 Ankle ﬂare
Subclinical edema
2 Edema
Pigmentation
Lipodermatosclerosis
White (skin) atrophy
3 Leg ulcer
Leg ulcer in the past
Table V. CEAP classiﬁcation30
Class Signs
0 No visible or palpable signs of venous disease
1 Telangiectases, reticular veins, malleolar ﬂare
2 Varicose veins
3 Edema without skin changes
4 Skin changes ascribed to venous disease (pigmentation,
venous eczema, lipodermatosclerosis)
5 Skin changes as above with healed ulceration
6 Skin changes as above with active ulceration
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Each limb is categorized according to objective signs into
one of seven classes (C0-C6; Table V). A higher class may
have any or all of the ﬁndings that deﬁne a less severe cate-
gory. Each limb is also scored as to whether it is symptomatic
(C0-6,S), or asymptomatic (C0-6,A). The diseased limb is then
classiﬁed by whether the etiology of the venous disorder is
congenital, primary, or secondary (EC, EP, ES). The
anatomic sites of venous disease are then denoted by AS for
superﬁcial sites, AD for deep sites, and AP for perforating
sites. Any or all systemsmay be involved. For example, AS,D,P
indicates disease at all sites. Finally, the pathophysiologic
classiﬁcation indicates whether the venous disease is caused
by reﬂux (PR), obstruction (PO), or both (PR,O). The CEAP
classiﬁcation was used in several studies to diagnose
PTS13,15,31-36 and was used to categorize severity of PTS in
two of these studies.31,35 Although use of this score has
become widespread for chronic venous disease in general,
there are difﬁculties in using this system to score patients
with PTS. First, it involves alphabetic components that are
not quantiﬁable, making the patient groups more difﬁcult to
compare. Second, certain criteria used to classify clinical class
cannot change over time (eg, an active ulcer—CEAP class
6—may heal, but the patient’s disease score can never
decrease below class 5). Furthermore, there is no standard-
ization as to which CEAP classiﬁcation signiﬁes PTS. For
example, in a study by Yamaki et al36 into the factors pre-
dicting the development of PTS, the CEAP category C0-3S,
ES, AS,D,P, PR,O indicated no PTS, and the category C4-6S,
ES, AS,D,P, PR,O was used to diagnose PTS. However, other
studies used a clinical signs score$3 to diagnose PTS.13,15,32
Other studies used the clinical signs score not only to diag-
nose but also to classify the severity of PTS,31,35 but not in
a standardized way. Therefore, CEAP is not ideal as a PTS
scoring system, which would aim to examine the effect of
treatment as well as classify severity, and there is not yet an
agreed CEAP class that is universally used to diagnose PTS.
Venous Clinical Severity Score. As a result of the
difﬁculties posed by the alphabetical elements of the
CEAP score and the fact that it is limited in its ability to
assess change over time, the Venous Clinical Severity Score
(VCSS) was developed,37 which is based on the CEAP
classiﬁcation and attributes scores to nine clinicaldescriptors, marked from 0 to 3 according to severity.
Another 0 to 3 points are allocated according to differences
in background conservative therapy (ie, whether elastic
stockings were used, and patient compliance with this
treatment) to produce a score out of 30 (Table VI). The
VCSS was used as an evaluation of endovascular treatment
of PTS in a study by Wahlgren et al,38 but there is no
standard VCS score to diagnose or grade the severity of
PTS. In the study by Kolbach et al22 investigating the
differences between the scoring systems, the VCSS showed
a poor correlation with all other scoring systems (k ¼ 0.22-
0.41). In addition, a validity study by Meissner et al39
examining the performance characteristics of the VCSS in
assessing chronic venous disease showed that although the
VCSS showed a good correlation with the CEAP score,
there was statistically signiﬁcant interobserver variability
when assessing the component descriptors of pain,
Table VI. VCSS37
Descriptor Score ¼ 0 Score ¼ 1 Score ¼ 2 Score ¼ 3
Pain None Occasional, not restricting
activity, or requiring
analgesia
Daily, moderate limitation
of activity, occasional
analgesia
Daily, severe limitation of
activities, or requiring
regular analgesia
Varicose veins (>4-mm
diameter)
None Few, scattered: branch
varicosities
Multiple: GS varicose veins
conﬁned to calf or thigh
Extensive: thigh and calf or
GS and LS distribution
Venous edema None Evening ankle edema only Afternoon edema, above
ankle
Morning edema above ankle
and requiring change of
activities
Skin pigmentation None, or focal,
low intensity
(tan)
Diffuse, but limited in area
and old (brown)
Diffuse over most of gaiter
distribution (lower third)
or recent pigmentation
(purple)
Wider distribution (above
lower third) and recent
pigmentation
Inﬂammation None Mild cellulitis, limited to
marginal area around
ulcer
Moderate cellulitis, involves
most of gaiter area (lower
third)
Severe cellulitis (lower third
and above) or signiﬁcant
venous eczema
Induration None Focal, circummalleolar
(<5 cm)
Medial or lateral, less than
lower third of leg
Entire lower third of leg or
more
No. of active ulcers 0 1 2 >2
Duration of active
ulceration, months
None <3 3-12 Not healed after 12 months
Diameter of largest
ulcer, cm
None <2 2-6 >6
Compressive therapy Not used or
noncompliant
Intermittent use of
stockings
Wears elastic stocking most
days
Full compliance
GS, Great saphenous; LS, lesser saphenous; VCSS, Venous Clinical Severity Score.
Table VII. Comparison of the different PTS scoring systems
Criteria Villalta Ginsberg Brandjes Widmer VCSS
Interobserver reliability Yes No evidence No evidence No evidence No evidencea
Association with AVP Yes Yes Yes Yes Yes
Association with patient quality-of-life scores Yes Yes No evidence No evidence No evidence
Validity Yes Yes Yes Yes Yes
Ability to assess PTS severity Yes No Yes Yes Yes
Ability to assess change over time/with treatment Yes No No No Yes
AVP, Ambulatory venous pressure; PTS, post-thrombotic syndrome; VCSS, Venous Clinical Severity Score.
aInterobserver reliability shown for chronic venous disease only, not for PTS.
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VCSS does address some of the obstacles posed by the
CEAP score, it has not yet been used in many studies
concerning PTS, and it does not correlate well with exist-
ing scoring systems.
DISCUSSION
An ideal scoring system for PTS should be easy to use,
valid, speciﬁc, have good interobserver reliability, be
acceptable to patients, have a clear association with the
pathophysiologic mechanism, and be able to categorize
according to disease severity and identify improvement or
deterioration in the condition. From the available evidence,
only the Villalta score can lay claim to all of these features
(Tables VII and VIII). It could be argued that the subjec-
tive criteria involved in calculating the score could reduce
its reliability, and that perhaps further investigation into
inter- and intraobserver reliability would be useful before
the score was used in everyday practice. However, theVillalta score appears to be the most commonly used due
to its ease and versatility of use in diagnosis, categorization
of severity, and in follow-up. Indeed, in 2008 it was recom-
mended at the International Society on Thrombosis and
Haemostasis in Vienna that the Villalta scoring system be
utilized in clinical trials as the scoring system of choice
for the diagnosis and grading of PTS.40
One caveat affecting all the different scoring systems
concerns their validity. Without knowing the exact patho-
physiologic process underlying the development of PTS,
the scores are only able to measure markers of the disease,
such as clinical features, AVPs, and patient symptoms.
Thus, no score can be said to be truly valid because there
is no clearly deﬁned measurement that can correlate with
PTS. Furthermore, only a few studies have examined
whether the different scoring systems correlate with the
markers of PTS mentioned earlier.6,21,22,25 Although valid-
ity testing in this manner ensures that the scoring system is
sensitive and speciﬁc for the condition for which it has been
Table VIII. Literature illustrating the properties of the different PTS scoring systems
Villalta Ginsberg Brandjes Widmer VCSS
Interobserver reliability Rodger et al20 (2008) No evidence No evidence No evidence No evidence
Association with
pathophysiology
Kolbach et al22 (2005)
Kahn et al25 (2006)
Kahn et al25 (2006) Kolbach et al22 (2005) Kolbach et al22
(2005)
Kolbach et al22
(2005)
Validity Kahn et al6 (2002)
Kahn et al21 (2008)
Kolbach et al22 (2005)
Kahn et al25 (2006)
Kahn et al25 (2006) Kolbach et al22 (2005) Kolbach et al22
(2005)
Kolbach et al22
(2005)
Diagnosis Prandoni et al2 (1996)
van Dongen et al10
(2005)
Tick et al11 (2008)
Kahn et al12 (2005)
Roumen-Klappe et al13
(2009)
Kahn et al14 (2005)
Roumen-Klappe et al15
(2009)
Ginsberg et al5 (2000)
Kahn et al24 (2007)
Brandjes et al4 (1997) Widmer et al28
(1981)
Kolbach et al29
(2003)
No evidence
Categorization of
severity
Kahn et al6 (2002)
Kahn et al17 (2011)
No Yes Yes No evidence
Identify change in
condition
Yes No No No Yes
Evaluation of treatment
for PTS
Kahn et al17 (2011)
O’Donnell et al18
(2008)
Prandoni19 (2005)
Ginsberg et al23 (2001) No evidence No evidence Wahlgren et al38
(2010)
PTS, Post-thrombotic syndrome; VCSS, Venous Clinical Severity Score.
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markers of the disease do not always correlate with clinical
symptoms, this can give conﬂicting results.
It also could be argued that an assessment of the
impact of venous disease on a patient’s quality of life should
be part of a PTS score. As demonstrated in the study by
Kahn et al,6 patients with PTS have a signiﬁcantly
decreased quality of life, and this in itself is a symptom
that contributes to the severity of the condition. Conse-
quently, a quality-of-life questionnaire, such as the
VEINES-QOL and VEINES-Sym,41 in combination with
the Villalta score, may aid in further clarifying the
differences in the categories of severity of the condition
and standardize some of the subjective criteria of the
Villalta score.
CONCLUSIONS
PTS is a serious and debilitating condition. Although
clinical research to identify the optimal management
options has been conducted, the optimal method of
deﬁning and classifying PTS has been unclear. From look-
ing at the studies conducted thus far, the frequency with
which the Villalta score is used reﬂects its desirable proper-
ties, namely, its ease of use, its ﬂexibility in being used for
diagnosis, classiﬁcation, and evaluation of treatment, and
its validity. If the Villalta score were combined with
a quality-of-life questionnaire, we believe this would
further strengthen the validity of the score. As such, we
recommend that the Villalta score combined with a venous
disease–speciﬁc quality-of-life questionnaire be consideredas the “gold standard” for the diagnosis and classiﬁcation
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